GLP Watchdog

GoodRx vs Ivy Rx

Neither GoodRx nor Ivy Rx has an FDA warning letter on record. No price lines up like for like: GoodRx and Ivy Rx publish prices for different products.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

GoodRx / Ivy Rx

GoodRx logo

GoodRx

7.8/10

Ivy Rx logo

Ivy Rx

7.3/10

FDA warning letters
None on record
None on record
Pharmacy
Brand-name only; no compounding
None named in our record
Lowest standing price
$149/moFoundayo (orforglipron) pill
$197/moCompounded semaglutide injection
States
48 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit GoodRx
Visit Ivy Rx

Neither GoodRx nor Ivy Rx pays us. Links to them earn nothing. Scores: GoodRx 7.8, Ivy Rx 7.3. How we are paid

What the record shows

  1. 01

    Neither GoodRx nor Ivy Rx has an FDA warning letter on record.

  2. 02

    Ivy Rx names no compounding pharmacy in our record. GoodRx sells brand-name medication only.

  3. 03

    No price lines up like for like: GoodRx and Ivy Rx publish prices for different products.

  4. 04

    Only GoodRx lists a price for brand-name tirzepatide pen and Foundayo (orforglipron) pill. Only Ivy Rx lists a price for compounded semaglutide injection and compounded tirzepatide injection.

  5. 05

    Ivy Rx covers two states GoodRx does not.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

GoodRx

Ivy Rx

Compounded semaglutide injection
Not sold or not priced

$197/mo

$2,364 a year

Compounded tirzepatide injection
Not sold or not priced

$297/mo

$3,564 a year

Brand-name tirzepatide pen

$299/mo

$3,588 a year

Not sold or not priced
Foundayo (orforglipron) pill

$149/mo

$1,788 a year

Not sold or not priced
Price includes
Not stated
Medication, clinician visits, shipping
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None
Refunds
Services and medication are generally non-refundable
All transactions are final; no returns
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. GoodRx: October 30, 2026. Ivy Rx: July 10, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for GoodRx

7.8/10
  • Sells brand-name tirzepatide pen and Foundayo (orforglipron) pill, which Ivy Rx does not price
Visit GoodRx

The case for Ivy Rx

7.3/10
  • Sells compounded semaglutide injection and compounded tirzepatide injection, which GoodRx does not price
  • Names no compounding pharmacy
Visit Ivy Rx

Scores

GoodRx 7.8 · Ivy Rx 7.3 out of 10. Six weighted parts.

Value25%

8.7A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

5.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
7.5

Accessibility10%

9.7A
vs
B
10.0

Support10%

5.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

GoodRx vs Ivy Rx: questions

Neither GoodRx nor Ivy Rx has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Ivy Rx names no compounding pharmacy in our record. GoodRx sells brand-name medication only.
No price lines up like for like: GoodRx and Ivy Rx publish prices for different products. We only set two prices against each other when they are for the same product and both are standing month-to-month or 4-week rates.
GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable. Ivy Rx states you can cancel at any time; refunds: all transactions are final; no returns.
Neither GoodRx nor Ivy Rx pays us. Links to them earn nothing. Scores: GoodRx 7.8, Ivy Rx 7.3.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks